NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free ENLV Stock Alerts $1.31 -0.07 (-5.07%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.3650-Day Range$1.27▼$4.3152-Week Range$1.15▼$4.59Volume41,924 shsAverage Volume144,721 shsMarket Capitalization$24.37 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Enlivex Therapeutics alerts: Email Address Enlivex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside434.4% Upside$7.00 Price TargetShort InterestHealthy1.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.86) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.38 out of 5 starsMedical Sector334th out of 932 stocksPharmaceutical Preparations Industry151st out of 437 stocks 3.5 Analyst's Opinion Consensus RatingEnlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.24% of the outstanding shares of Enlivex Therapeutics have been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 12.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENLV. Previous Next 3.9 News and Social Media Coverage News SentimentEnlivex Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enlivex Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for ENLV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enlivex Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Enlivex Therapeutics Stock (NASDAQ:ENLV)Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Read More ENLV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENLV Stock News HeadlinesMay 29 at 4:15 PM | globenewswire.comEnlivex Therapeutics Closes up to $15 Million Registered Direct OfferingMay 28 at 8:12 AM | globenewswire.comEnlivex Therapeutics Announces up to $15 Million Registered Direct OfferingMay 21, 2024 | finance.yahoo.comWe're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn RateApril 29, 2024 | finance.yahoo.comEnlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsApril 22, 2024 | finance.yahoo.comEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisApril 18, 2024 | msn.comYet Another Biotech Stock Has Found Success During Tuesday's SessionApril 17, 2024 | msn.comEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14April 16, 2024 | finance.yahoo.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | globenewswire.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 13, 2024 | stockhouse.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With SepsisApril 11, 2024 | finance.yahoo.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | globenewswire.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | msn.comNasdaq Gains Over 50 Points; US Producer Prices Increase In MarchApril 11, 2024 | msn.comEnlivex stock plunges 50% on mixed results from sepsis studyApril 11, 2024 | msn.comDow Dips 100 Points; CarMax Earnings Miss ViewsApril 11, 2024 | globenewswire.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisApril 5, 2024 | msn.comENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023March 22, 2024 | finanznachrichten.deEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 16, 2024 | finance.yahoo.comENLV Apr 2024 7.500 callMarch 9, 2024 | edition.cnn.comEnlivex Therapeutics Ltd.February 26, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee OsteoarthritisFebruary 22, 2024 | benzinga.comEnlivex Therapeutics Stock (NASDAQ:ENLV), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comENLV May 2024 5.000 putFebruary 7, 2024 | finance.yahoo.comEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodJanuary 17, 2024 | finance.yahoo.comEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisSee More Headlines Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/29/2024Next Earnings (Estimated)6/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENLV CUSIPN/A CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+434.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-71.00% Return on Assets-59.08% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.81Miscellaneous Outstanding Shares18,600,000Free Float16,315,000Market Cap$24.37 million OptionableOptionable Beta1.22 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Shai Novik M.B.A. (Age 58)Executive Chairman Comp: $528kDr. Oren Hershkovitz Ph.D. (Age 47)Chief Executive Officer Comp: $273.6kMs. Shachar Shlosberger CPA (Age 47)Chief Financial Officer Comp: $126kMr. Veronique Amor-BaroukhSenior Director of OperationsMs. Sigal AradDirector of HRKey CompetitorsOrgenesisNASDAQ:ORGSClearside BiomedicalNASDAQ:CLSDConnect BiopharmaNASDAQ:CNTBProPhase LabsNASDAQ:PRPHLifeVantageNASDAQ:LFVNView All Competitors ENLV Stock Analysis - Frequently Asked Questions Should I buy or sell Enlivex Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENLV shares. View ENLV analyst ratings or view top-rated stocks. What is Enlivex Therapeutics' stock price target for 2024? 1 analysts have issued 1 year price targets for Enlivex Therapeutics' shares. Their ENLV share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 434.4% from the stock's current price. View analysts price targets for ENLV or view top-rated stocks among Wall Street analysts. How have ENLV shares performed in 2024? Enlivex Therapeutics' stock was trading at $2.70 on January 1st, 2024. Since then, ENLV stock has decreased by 51.5% and is now trading at $1.31. View the best growth stocks for 2024 here. Are investors shorting Enlivex Therapeutics? Enlivex Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 230,600 shares, a drop of 12.4% from the April 30th total of 263,200 shares. Based on an average daily volume of 173,600 shares, the days-to-cover ratio is currently 1.3 days. View Enlivex Therapeutics' Short Interest. When is Enlivex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024. View our ENLV earnings forecast. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) posted its earnings results on Friday, March, 29th. The company reported ($0.48) EPS for the quarter. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENLV) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWrite this ticker symbol down…StocksToTradeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWho are Nvidia’s New Silent Partners?Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
